SCIP offers an opportunity to improve adherence to secondary prophylaxis in Māori and Pacific patients with acute rheumatic fever (ARF), according to a recent study, and has the potential to improve health outcomes. SCIP enables injections to be given every 10 weeks as an alternative to the standard 4-weekly intramuscular injections. Semi-structured interviews were conducted with Māori and Pacific patients with ARF who had been receiving SCIP for ≥1 year, and their families (n = 10), between March and August 2024. Key themes associated with SCIP use were: 1) reduced burden of treatment; 2) emotional impact from reduced injection frequency; 3) family-centered care by healthcare providers; 4) relationship building; 5) health literacy; and 6) pain management. Overall, the extended dosing interval provided by SCIP reduced the physical and emotional burden on patients, thereby enhancing quality of life.